Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
GLYCERYL TRINITRATE
UCB Pharma Limited
5 Mg/day
Transdermal Patch
2009-10-30
IRISH MEDICINES BOARD ACTS 1995 AND 2006 MEDICINAL PRODUCTS(CONTROL OF PLACING ON THE MARKET)REGULATIONS,2007 (S.I. NO.540 OF 2007) PA0365/088/001 Case No: 2072855 The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to Transferred from PA0271/007/001. UCB PHARMA LIMITED 208 BATH ROAD, SLOUGH, BERKSHIRE SL1 3WE, UNITED KINGDOM an authorisation, subject to the provisions of the said Regulations, in respect of the product DEPONIT 5MG/24 HOURS TRANSDERMAL PATCH The particulars of which are set out in Part I and Part II of the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document. This authorisation, unless previously revoked, shall continue in force from 30/10/2009. Signed on behalf of the Irish Medicines Board this ________________ A person authorised in that behalf by the said Board. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 30/10/2009_ _CRN 2072855_ _page number: 1_ PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Deponit 5 mg/24 hours Transdermal Patch 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each transdermal patch contains 18.7 mg of glyceryl trinitrate in a patch size of 9cm 2 , releasing a nominal 5 mg of glyceryl trinitrate per 24 hours. For excipients, see section 6.1. 3 PHARMACEUTICAL FORM Transdermal Patch White, translucent square patch with convex round corners with “deponit 5” marked on the outer face. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Prophylaxis of angina pectoris alone or in combination with other anti-anginal therapy. 4.2 POSOLOGY AND METHOD OF ADMINIST Read the complete document